Studies Validate IL-17 as Hidradenitis Suppurativa Drug Target

Two phase 3 studies with the IL-17 inhibitor bimekizumab for moderate-to-severe hidradenitis suppurativa generate clinically meaningful results, researchers report.
Medscape Medical News

source https://www.medscape.com/viewarticle/989861?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost